Session Title: Vascular Diseases III
Session Date/Time: Sunday 29/09/2013 | 08:00-10:00
Paper Time: 08:24
Venue: Hall 3 (Level 0)
First Author: M.Gajdosova SLOVAKIA
Co Author(s): M. Ondrejkova
To report the clinical course of the pregnancy after intravitreal treatment with bevacizumab
OFTAL s.r.o, Specialized Ophtalmology Hospital, Zvolen, Slovakia
- Case report: 27 years old woman with active choroidal neovascularisation (CNV) of inflammatory origin (HSV positivity) above the fovea in her right eye was administered intravitreal (ivt) injections of bevacizumab, after discussing the treatment-related risks and benefits.
In the beginning her BCVA was 30 ETDRS letter score and CRT 793 um. After 3 ivt injections of bevacizumab (1,25mg in 0,05 ml) BCVA substantionaly improved to 59 ETDRS letters score (+29 letters gain) and CRT decreased to 223 um (-570 um reduction). After 3rd injection, 8 week of pregnancy was confirmed. During pregnancy, fetal ultrasound and ophthalmic examination were performed monthly. BCVA and OCT stayed stable and did not required any further ivt treatment. She had an uneventful prenatal course and delivered a healthy full-term infant.
In this case ivt anti-VEGF therapy lead to significant BCVA improvement and stabilisation of CNV. Despite of ivt administration of the last dose of bevacizumab in the beginning of the pregnancy, this was not accompanied by any negative systemic side effects in both mother and the fetus. Further studies are warranted to provide more detailed information about this treatment and the related risks in pregnant women.